Spain's government and Farmaindustria link on Protocol for sustainability, access and innovation

9 November 2015

Trade group Farmaindustria and Spain’s Ministries of Finance and Public Administrations and of Health, Social Services and Equality last week signed a Protocol of Collaboration – aimed at guaranteeing the sustainability of the Spanish NHS (SNS) and access to innovation.

The signing was carried out an event held at the premises of the Ministry of Health, with the presence of Ministers Cristobal Montoro and Alfonso Alonso, and the president of Farmaindustria, Antoni Esteve, and also the Secretary of State of Public Administrations, Antonio Beteta.

This Protocol will have duration of 12-months starting on December 1, with the possibility of it being extended annually, up to a maximum of three years. It is based on the reconciling of objectives and the State’s commitments with regards to public deficit and sustainability of the SNS, to health care and pharmaceutical needs for the population and to the future challenges of an industrial sector which is key to the Spanish economy such as the pharmaceutical sector. In this regard, the president of Farmaindustria highlighted that “this agreement is a clear sign of the Spanish Government’s commitment and the pharmaceutical industry’s with citizens’ healthcare and with the economic and social reality of Spain.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical